Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

RIPK4 Downregulation Reduces ABCG2 Expression, Increasing BRAF-Mutated Melanoma Cell Susceptibility to Cisplatin- and Doxorubicin-Induced Apoptosis.

Biomolecules - 10 Dec 2024

Olajossy Bartlomiej, Wronski Norbert, Madej Ewelina, Komperda Joanna, Szczygieł Małgorzata, Wolnicka-Glubisz Agnieszka

Abstract excerpt

Melanoma cells remain resistant to chemotherapy with cisplatin (CisPt) and doxorubicin (DOX). The abnormal expression of Receptor-Interacting Protein Kinase 4 (RIPK4) in certain melanomas contributes to tumour growth through the NFκB and Wnt/β-catenin signalling pathways, which are known to regulate chemoresistance and recurrence. Despite this, the role of RIPK4 in response to chemotherapeutics in melanoma has...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to ATP Binding Cassette Transporter, Subfamily G, Member 2
Share to Cisplatin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Down-Regulation

Share to Doxorubicin

Share to Drug Resistance, Neoplasm

Share to Melanoma

Share to Neoplasm Proteins

Share to Proto-Oncogene Proteins B-raf

Source

Open in PubMed Open full text

Identifiers

PMID: 39766280
DOI: 10.3390/biom14121573
PMCID: PMC11674099

Genes

RIPK4
ABCG2
BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

RIPK4 Downregulation Reduces ABCG2 Expression, Increasing BRAF-Mutated Melanoma Cell Susceptibility to Cisplatin- and Doxorubicin-Induced Apoptosis.PMID 39766280Read ↗

Effects of PD-L1 Inhibitors on Mitochondrial Function in Melanoma A375 Cells: Unveiling a Shielded Drug Resistance MechanismSemantic proximity Read ↗

Combinatorial Treatment with PARP and MAPK Inhibitors Overcomes Phenotype Switch-Driven Drug Resistance in Advanced Melanoma.Semantic proximity Read ↗

Mitochondrial Signatures Shape Phenotype Switching and Apoptosis in Response to PLK1 and RSK Inhibitors in MelanomaSemantic proximity Read ↗

ABCB8 Mediates Doxorubicin Resistance in Melanoma Cells by Protecting the Mitochondrial GenomeSemantic proximity Read ↗

PD-L1 up-regulation in melanoma increases disease aggressiveness and is mediated through miR-17-5pSemantic proximity Read ↗

Combined PARP14 Inhibition and PD-1 Blockade Promotes Cytotoxic T Cell Quiescence and Modulates Macrophage Polarization in Relapsed MelanomaSemantic proximity Read ↗

The Cell-Cycle Regulator CDK4: An Emerging Therapeutic Target in MelanomaSemantic proximity Read ↗

CDK6-PI3K signaling axis is an efficient target for attenuating ABCB1/P-gp mediated multi-drug resistance (MDR) in cancer cellsSemantic proximity Read ↗

RIG-I immunotherapy overcomes radioresistance in p53-positive malignant melanomaSemantic proximity Read ↗

Effect of ABT-888 on the apoptosis, motility and invasiveness of BRAFi-resistant melanoma cells.Semantic proximity Read ↗

Class I-specific histone deacetylase inhibitor MS-275 overrides TRAIL-resistance in melanoma cells by downregulating c-FLIPSemantic proximity Read ↗

Triggering necroptosis in cisplatin and IAP antagonist-resistant ovarian carcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.